Multiple Myeloma

A maintenance regimen of lenalidomide (Revli-mid) and elotuzumab (Empliciti) after autologous stem cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
On February 22, 2017, the US Food and Drug Administration (FDA) approved lenalidomide (Revlimid; Celgene), an oral IMiD, for maintenance therapy after autologous HSCT in patients with multiple myeloma.
Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
Recent advances in the treatment of multiple myeloma have dramatically altered the trajectory of disease, as providers now have several efficacious agents in various drug classes at their disposal.
Despite major and continuing treatment interventions, myeloma remains incurable for most patients, and relapse is an expected part of the disease course. At the National Comprehensive Cancer Network 12th Annual Congress: Hematologic Malignancies, Natalie S. Callander, MD, outlined issues in the management of relapsed/refractory multiple myeloma (RRMM).
Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a proteasome inhibitor, was approved by the FDA on June 16, 2017.
The past decade has witnessed dramatic progress in the treatment of multiple myeloma (MM), which has resulted in unprecedented improvements in survival outcomes.
Page 1 of 2
Results 1 - 10 of 12

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code